Kyverna Therapeutics (KYTX) News Today

Kyverna Therapeutics, Inc. (NASDAQ: KYTX) traded broadly flat with a slight upward bias as investors weighed improving analyst estimates and reported progress toward regulatory approval against the company’s continuing losses and mixed analyst sentiment.

• Positive Sentiment: HC Wainwright raised its estimates across multiple periods, including FY2026 EPS to a loss of $2.70 from $2.98 and FY2027 EPS to a loss of $2.79 from $3.01. The firm maintained a Buy rating and a $25 price target, implying substantial upside from recent trading levels. MarketBeat Kyverna Therapeutics analyst estimates
• Positive Sentiment: The revised forecasts also improved expected quarterly results for Q3 and Q4 2026 and Q1 through Q4 2027, suggesting HC Wainwright sees a better earnings trajectory, although KYTX is still expected to remain unprofitable. The company recently beat quarterly EPS expectations, reporting a $0.63 loss versus the $0.68 consensus loss.
• Positive Sentiment: Kyverna’s reported progress toward potential approval supports the long-term investment case because successful regulatory advancement could improve the prospects for its cell-therapy platform. Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval
• Neutral Sentiment: Despite the favorable HC Wainwright view, broader analyst opinions on KYTX remain mixed. That lack of consensus likely limited the stock’s reaction to the improved estimates and approval-related progress. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: Kyverna remains a development-stage biotechnology company with substantial expected losses, making the stock highly dependent on clinical, regulatory and financing progress. Its beta of 1.93 also indicates elevated volatility.